CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities:
Net Income (Loss)	$ 48,893	$ 96,825
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	31,237	23,933
Amortization of debt issuance costs	914	905
Stock-based compensation	12,737	14,900
Deferred income taxes, net	(2,196)	738
Contingent consideration	3,026	(9,295)
Noncash interest income	(2,023)	0
Other	574	276
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable	(4,606)	(8,433)
Inventories	(2,508)	(58,106)
Prepaid expenses and other assets	(11,530)	2,402
Operating lease right of use assets	6,487	(21,457)
Other assets	(888)	(406)
Accounts payable	(3,871)	6,322
Accrued expenses	(26,234)	(4,014)
Operating lease Liabilities	(4,544)	23,852
Long-term liabilities	154	392
Total cash provided by operating activities	45,622	68,834
Cash flows from investing activities:
Acquisitions, net of cash acquired	(28,099)	0
Proceeds from maturity of marketable securities held to maturity	102,323	0
Additions to capitalized software costs	(2,075)	(1,875)
Purchases of property, plant and equipment	(16,749)	(52,576)
Other investing activities	0	17
Total cash provided by (used in) investing activities	55,400	(54,434)
Cash flows from financing activities:
Proceeds from exercise of stock options	62	463
Payment of tax withholding obligation on vesting of restricted stock	(11,140)	(14,759)
Repayment of Convertible Senior Notes	(9)	(18)
Payment of earnout consideration	(7,298)	0
Proceeds from issuance of common stock, net	(3)	0
Total cash used in financing activities	(18,388)	(14,314)
Effect of exchange rate changes on cash and cash equivalents	(2,436)	(7,388)
Net increase (decrease) in cash and cash equivalents	80,198	(7,302)
Cash, cash equivalents and restricted cash, beginning of period	523,458	603,814
Cash and cash equivalents, end of period	603,656	596,512
Supplemental disclosure of non-cash investing and financing activities:
Assets acquired under operating leases	831	21,739
FlexBiosys, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of common stock issued for acquisition	5,243	0
Avitide, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of contingent consideration earnouts related to acquisition	$ 7,229	$ 0